We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sofusa System With Sumatriptan (KC5010) Phase 1 Pharmacokinetics and Safety Study (KCC-SMT-002) (KCC-SMT-002)

This study is not yet open for participant recruitment.
Verified August 2017 by Kimberly-Clark Corporation
Sponsor:
ClinicalTrials.gov Identifier:
NCT03229798
First Posted: July 26, 2017
Last Update Posted: August 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Kimberly-Clark Corporation
  Purpose
Study KCC-SMT-002, is a Phase 1, single-site, open-label, non-randomized, crossover, flexible dose design study to investigate the pharmacokinetic (PK) and safety comparing the Sofusa™ system with sumatriptan (KC5010) to Imitrex® oral tablets in 17 healthy volunteers.

Condition Intervention Phase
Migraine Disorders Drug: Sumatriptan Succinate Oral Tablet Combination Product: Transdermal delivery of sumatriptan succinate Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 1 Study to Establish the Pharmacokinetics and Safety of Sumatriptan Succinate Administered Via the Sofusa™ Device at Variable Doses Compared to Oral Imitrex® Single 100 mg Dose in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by Kimberly-Clark Corporation:

Primary Outcome Measures:
  • PK Cmax [ Time Frame: 48 hours after dosing begins ]
    Pharmacokinetic profile with Cmax (maximum concentration) of drug in blood, ng/mL

  • PK AUC [ Time Frame: 48 hours after dosing begins ]
    Pharmacokinetic profile AUC (area under the curve) of drug in blood, ng-hr/mL


Secondary Outcome Measures:
  • Dermatological skin response (Draize scale) [ Time Frame: From Predose to 168 hours after device application ]
    Skin response as measured on modified Draize scale (erythema, edema, etc.)

  • Pain of application and wear (VAS scale) [ Time Frame: Upon application and after wear ]
    Pain as reported on Visual Analog Scale


Estimated Enrollment: 17
Anticipated Study Start Date: October 2017
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sumatriptan Succinate Oral Tablet
100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
Drug: Sumatriptan Succinate Oral Tablet
Sumatriptan succinate commercial Imitrex 100 mg tablet
Experimental: Sofusa Profile #1
Combination device for transdermal delivery of sumatriptan succinate
Combination Product: Transdermal delivery of sumatriptan succinate
Sumatriptan succinate transdermal drug delivery system
Other Names:
  • Sofusa DoseDisc
  • Sofusa DoseConnect
  • KC5010
Experimental: Sofusa Dose Profile #2
Combination device for transdermal delivery of sumatriptan succinate- adjust flow rate to acheive PK profile based on results from Sofusa Dose Profile #1
Combination Product: Transdermal delivery of sumatriptan succinate
Sumatriptan succinate transdermal drug delivery system
Other Names:
  • Sofusa DoseDisc
  • Sofusa DoseConnect
  • KC5010
Experimental: Sofusa Dose Profile #3
Combination device for transdermal delivery of sumatriptan succinate- adjust flow rate to acheive PK profile based on results from Sofusa Dose Profiles #1 & #2
Combination Product: Transdermal delivery of sumatriptan succinate
Sumatriptan succinate transdermal drug delivery system
Other Names:
  • Sofusa DoseDisc
  • Sofusa DoseConnect
  • KC5010

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Able to give voluntary written informed consent (personally signed and dated) and HIPPA Authorization prior to any study related procedures.
  2. Available to participate for the entire study period.
  3. Be a male or female person between 18 and 55 years (inclusive) of age.
  4. Healthy as determined by the investigator based on a medical evaluation including history, physical examination, electrocardiogram (ECG), and laboratory tests.
  5. Have systolic blood pressure (sitting) of < 140 mmHg and diastolic blood pressure of < 90 mmHg after 5 minutes of rest. Minor excursions in blood pressure outside of this range may be acceptable if determined not to be clinically significant by the study physician or medical monitor.
  6. Have resting pulse rate (sitting) within normal range of 60-100 bpm. Minor excursions in resting pulse outside of this range may be acceptable if determined not to be clinically significant by the study physician or the medical monitor.
  7. Females must be either postmenopausal for at least 1 year, surgically sterile (bilateral oophorectomy, tubal ligation, tubal occlusion, hysterectomy), or using adequate contraception from screening until 90 days after completion of study participation. Adequate contraception is defined as true abstinence, a vasectomized partner, or one of the following in combination with a diaphragm, cervical cap, or a condom:

    • Hormonal contraceptives (oral, implant, patch, injection)
    • Intrauterine device

    Males must use adequate contraception and must not donate sperm from first admission to the clinical research center until 90 days after completion of study participation. Adequate contraception is defined as true abstinence, vasectomy, a partner who is surgically sterile (bilateral oophorectomy, tubal ligation, tubal occlusion, hysterectomy), or one of the following in combination with a diaphragm, cervical cap, or a condom:

    • Hormonal contraceptives (oral, implant, patch, injection)
    • Intrauterine device
  8. Have a body weight above 50 kg and below 90 kg (inclusive).
  9. Have a forearm circumference between 15 and 24 cm (6" to 9.5") in the area between 5 cm (2") from the wrist toward the elbow and 5 cm (2") from the elbow to the wrist.
  10. Be able to communicate effectively with the study personnel and understand and comply with all study requirements.

Exclusion Criteria:

  1. Women who are pregnant or lactating.
  2. Current use or has used tobacco- or nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, etc.) 30 days prior to investigational product administration. A cotinine test (with a cut-off of 200 mg) will be performed at screening and admission to the study center.
  3. A positive screening result for human immunodeficiency virus (HIV) antibody, Hepatitis B surface antigen (HBsAg), or Hepatitis C antibody (anti-HCV).
  4. Any disease or condition (medical or surgical) that might compromise a major body system (e.g. cardiovascular, respiratory, etc.) or conditions that may interfere with the absorption, distribution, metabolism, or excretion of the study medication.
  5. Participation in the treatment phase of a clinical study or receipt of an investigational drug or medical device within 30 days prior to the Treatment visit for dosing.
  6. Presence or history of hypertension or other cardiovascular abnormalities such as, but not limited to, myocardial infarction, heart failure, arrhythmia, stroke, or peripheral vascular disease or any other cardiovascular disease that requires the subject to wear a pacemaker.
  7. Use of a drug therapy known to induce or inhibit hepatic drug metabolism within 30 days prior to the Treatment visit for dosing.
  8. Patient has received a live attenuated vaccine within the 4 weeks prior to treatment or plans to receive one during the study.
  9. Has a positive history or known sensitivity to sumatriptan or other triptans.
  10. Any history of sensitivity to methylene blue, fluorescein, or calcein or other similar dye product.
  11. Subjects who use ergotamine-containing or ergot-type medications (like dihydrogergotamine or methysergide). The Imitrex® label specifies that these medication are contraindicated within 24 hours of use.
  12. Subjects who are currently taking certain prescription medications (such as MAO-A inhibitors, SSRIs. SNRIs, triptans or tricyclics) or over-the-counter medications (including vitamins and herbal preparations) that could interfere with the evaluation of the safety of the subject, as determined by the Investigator (subjects must have discontinued these medications for 5 or more half-lives prior to the Treatment visit for dosing). Specifically, the development of serotonin syndrome has been reported with use of methylene blue class products. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors).
  13. Positive screen for substances of abuse.
  14. Recent history (i.e. within 2 years) of alcohol abuse, illicit drug use, or significant mental illness.
  15. Febrile illness within 7 days of Treatment visit for dosing.
  16. History of difficulty with phlebotomy procedures.
  17. Donated blood (>400 mL) or blood products within 45 days prior to the Treatment visit for dosing.
  18. Subjects who have skin conditions or tattoos extensive enough to cover areas where the device is to be applied.
  19. Any history of skin contact sensitivity to metals, plastics or adhesives.
  20. Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03229798


Contacts
Contact: Russell F Ross, PhD (770) 861-0368 rross@kcc.com
Contact: Clinical Manager, PhD (678) 576-0000 egadsby@kcc.com

Sponsors and Collaborators
Kimberly-Clark Corporation
Investigators
Principal Investigator: Wayne L Harper, MD Carolina Phase I Research, LLC
  More Information

Additional Information:
Publications:
Responsible Party: Kimberly-Clark Corporation
ClinicalTrials.gov Identifier: NCT03229798     History of Changes
Other Study ID Numbers: REC-0000330
First Submitted: July 20, 2017
First Posted: July 26, 2017
Last Update Posted: August 18, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Sumatriptan
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs